CNSP vs. PULM, ADMP, ERNA, UPC, NCNA, OGEN, ADXN, SHPH, ABVC, and GRAY
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Pulmatrix (PULM), Adamis Pharmaceuticals (ADMP), Eterna Therapeutics (ERNA), Universe Pharmaceuticals (UPC), NuCana (NCNA), Oragenics (OGEN), Addex Therapeutics (ADXN), Shuttle Pharmaceuticals (SHPH), ABVC BioPharma (ABVC), and Graybug Vision (GRAY). These companies are all part of the "medical" sector.
CNS Pharmaceuticals (NASDAQ:CNSP) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
In the previous week, Pulmatrix had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 4 mentions for Pulmatrix and 2 mentions for CNS Pharmaceuticals. Pulmatrix's average media sentiment score of 0.72 beat CNS Pharmaceuticals' score of 0.43 indicating that Pulmatrix is being referred to more favorably in the news media.
14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 9.2% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
CNS Pharmaceuticals has a net margin of 0.00% compared to Pulmatrix's net margin of -75.73%. Pulmatrix's return on equity of -44.05% beat CNS Pharmaceuticals' return on equity.
CNS Pharmaceuticals has a beta of 2.78, indicating that its stock price is 178% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Pulmatrix has a consensus price target of $10.00, suggesting a potential upside of 434.76%. Given Pulmatrix's higher probable upside, analysts clearly believe Pulmatrix is more favorable than CNS Pharmaceuticals.
Pulmatrix has higher revenue and earnings than CNS Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Pulmatrix received 150 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 70.77% of users gave CNS Pharmaceuticals an outperform vote while only 51.85% of users gave Pulmatrix an outperform vote.
Summary
Pulmatrix beats CNS Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
